RxDoctor Payments DataLook up a doctor →

Sean Ormond, MD

Interventional Pain Medicine · Glendale, AZNPI 1699118943

Payments from drug & device makers

$11,328in general payments, 2019–2025

Across 586 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Boston Scientific$2K
  • Medtronic$560
  • Nalu Medical, Inc.$311
  • Globus Medical$221
  • Nevro Corp.$199
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$4994%
  • Food & beverage$10,80795%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,328 in reported general payments places this provider in the 50th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$414,547
Medicare patients
249
Services billed
11,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina14$18,104
BelbucaBuprenorphine Hcl16$7,742
Buprenorphine12$3,433
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen119$2,440
Oxycodone Hcl128$1,936
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$1,417
Pregabalin35$799
Naloxone Hcl15$794
Gabapentin76$738
Tizanidine Hcl68$617
Cephalexin41$383
Morphine Sulfate12$325
Hydromorphone Hcl30$302
Methocarbamol27$260
Cyclobenzaprine Hcl28$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$124$18,10414 claims
Collegium Pharmaceutical, Inc.Belbuca$84$7,74216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →